Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

TURNING
NATURE’S MIRACLE
INTO
MEDICAL
BREAKTHROUGHS

Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

COMPANY PIPELINE
PAUSE

BEST IN CLASS & SCALABLE
Cellular Medicine manufacturing

Featuring industry leading and diverse product lines

ALLOGENEIC PLATFORM
Built on two decades of science

Driven by a deep, seasoned management team

INNOVATIVE PLACENTA-DERIVED
T cells, NK Cells, and pluripotent stem cells

With greater expandability, persistence, and stem-ness

OUR MISSION

is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics

stemcell_full

OUR VISION

Harness the Unique Biology & Ready Availability of the Placenta

  • Unmet Global Need
    Significant unmet global need for allogeneic cellular medicines delivered on-demand, off-the-shelf
  • Groundbreaking Research
    Groundbreaking basic & translational research into the unique biological activity of placental-derived cells
  • Pioneering Technology
    Pioneering technology platform of placental-derived cellular medicines and advanced biomaterials
  • Industry Timing
    The time has arrived for cellular medicines that overcome barriers of scale, quality, and economics
COMPANY PIPELINE

Cellular Medicine Manufacturing

The Process is the Product

A fully integrated, purpose-built manufacturing, translational research and biobanking center

  • Purpose-built facility staffed by over 100 highly specialized scientists, engineers & technicians
  • 150,000 sq ft including laboratory and advanced manufacturing space for cellular medicine & biomaterials
  • Clinical Scale – (9) Grade C/ISO 7 suites and (6) Grade D/ISO 8 labs ALL GMP-CAPABLE
Tour Our Facility

The Latest From Our

NEWSROOM

Celularity Announces Full Year 2024 Operating and Financial Results

Celularity Announces Full Year 2024 Operating and Financial Results

Avatar photo
Celularity Inc.
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Avatar photo
Celularity Inc.
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology

Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology

Avatar photo
Celularity Inc.
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Avatar photo
Celularity Inc.

Celularity Inc. expansion is driven by experienced Cellular Medicine leaders & innovators with deep expertise in clinical development & regulatory approval.

Meet Our Board of Directors
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions